Document is current
Any future updates will be listed below
-
Authors
Kang, Hyunook https://orcid.org/0000-0002-7017-4597
Steigerwald, Ruben
Ullman, Elijah Z. https://orcid.org/0000-0002-6122-023X
Epstein, Max
Paladugu, Srinu
Liotta, Dennis C. https://orcid.org/0000-0002-7736-7113
Traynelis, Stephen F. https://orcid.org/0000-0002-3750-9615
Furukawa, Hiro https://orcid.org/0000-0001-8296-8426
- License Information
-
More Information
Article History
Received: 19 May 2025
Accepted: 30 September 2025
First Online: 29 October 2025
Competing interests
: S.F.T. and H.F. are members of the medical advisory boards for the CureGRIN Foundation. S.F.T. is an advisory board member for the GRIN2B Foundation; a member of the scientific advisory boards for Eumentis Therapeutics and Neurocrine; a consultant for GRIN Therapeutics and Seyltx; a co-founder of NeurOp and AgriThera; and is on the Board of Directors for NeurOp. D.C.L. is on the Board of Directors for NeurOp. Several authors (S.P., S.F.T. and D.C.L.) are co-inventors on Emory-owned IP involving NMDA receptor modulators. The other authors declare no competing interests.
